Latest Breaking News On - Konstanze diefenbach - Page 1 : vimarsana.com

Bayer initiates Phase III Studies with Investigational Contrast Agent Gadoquatrane

Comprehensive clinical development program called QUANTI includes two Phase III studies in adults and one pediatric study investigating gadoquatrane for use in MRI across all body regions and across ages from birth to adulthood 

Potentially safer MRI gadolinium-based contrast agent to enter testing | Scans used to diagnose, monitor MS

Ultravist Approval Expanded to Include Contrast-Enhanced Mammography

The FDA has approved Ultravist (iopromide) for contrast-enhanced mammography to visualize known or suspected lesions of the breast.

FDA approves Bayer's Ultravist (iopromide) Injection for Contrast-enhanced Mammography

Contrast-enhanced mammography (CEM) is an emerging modality combining digital mammography with the administration of a contrast agent 

Bayer initiates Phase III studies with investigational contrast agent gadoquatrane

WHIPPANY, N.J.--(BUSINESS WIRE)--Jun 27, 2023--

Bayer initiates Phase III studies with investigational contrast agent gadoquatrane

Bayer initiates Phase III studies with investigational contrast agent gadoquatrane

WHIPPANY, N.J.--(BUSINESS WIRE)--Jun 27, 2023--

Ultravist Approval Expanded to Include Contrast-Enhanced Mammography

The FDA has approved Ultravist (iopromide) for contrast-enhanced mammography to visualize known or suspected lesions of the breast.

FDA Approves Iopromide Injection for Contrast-Enhanced Mammography

The FDA has approved the first and only iodine-based contrast agent iopromide-300, -370 injection for intra-arterial and intravenous contrast-enhanced mammography.

FDA approves Bayer's Ultravist® (iopromide) injection for contrast-enhanced mammography